EP Global Communications Inc fka EPGL

[H8ster]

All that is fine and dandy, if you're dealing with an established company where the product has been selling for years. EPGL is new. It's a spec play. For a Spec play, you invest early before the numbers come out. Not afterwards, like you want investors to do.

So the PRIMARY concern of investors should NOT be proof of early sales numbers but whether or not EPGL is doing what is necessary to create and eventually grow sales numbers to a point, where after, at least a year of their product being on the market, justifies the given market cap.

As for evidence of efficacy of the MPDD, time will tell how doctors and patients take to the device. For now, all we have to go on is what the Norman Marcus Pain Institute did with it, and what the patients there said about it, which is on the Norman Marcus Pain Institute website.
MPDD Patient Testimonials

As well as what reviews are that are listed on the EPGL website.
MPDD Review #1
MPDD Review #2

Or you can read the published medical paper on the device.
MPDD Published Medical Paper

If you do enough DD, you can get a sense for the efficacy of the MPDD. And again, for a Spec play, if you wait for everything, you've waited too long. You have to except risk with these plays. You seem to think that there should be zero risk when investing in a biotech start-up. If that's the case you would never invest in one.

Proper risk assessment is all anybody has to do here. And they will fine that the potential reward will outweigh the risk.